Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8647181 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL8647178 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL19477874 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL2338780 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL20643514 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL10036857 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL19477779 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL22537923 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL21762059 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 | |
| SCHEMBL3986108 | 1.00 | LMNA (0.57) | LMNAKMT2APOLBALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113264970-B | Hymexazol oxygen glucoside conjugate and preparation and application thereof | 中国科学院海洋研究所 | 2023-01-24 | — | — | CN | claimed |
| CN-113264970-B | Hymexazol oxygen glucoside conjugate and preparation and application thereof | 中国科学院海洋研究所 | 2023-01-24 | — | — | CN | disclosed |
| US-20210205349-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
| EP-1742534-A2 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005116086-A2 | GLUCOSAMINE AND GLUCOSAMINE/ANTI-INFLAMMATORY MUTUAL PRODRUGS, COMPOSITIONS, AND METHODS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | LMNA 3810/4885KMT2A 2547/4885POLB 4628/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | LMNA 3539/4885KMT2A 2821/4885POLB 4705/4885 |
| US-20210205349-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | NGLY1, GALNT1, GALNT10 | LMNA 2369/4885KMT2A 4129/4885POLB 3957/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | LMNA 3539/4885KMT2A 2821/4885POLB 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.